Early non-infectious pulmonary complications represent a significant cause of mortality after hematopoietic cell transplantation (HCT). We tested the hypothesis that oral beclomethasone dipropionate (BDP) is effective for preventing early non-infectious pulmonary complications after allogeneic HCT. We retrospectively reviewed the medical records of 120 patients, 60 in each treatment arm, to identify non-infectious and infectious pulmonary events and pulmonary function test results from all patients who participated in two randomized trials of oral BDP for treatment of acute gastrointestinal GVHD. 17-Beclomethasone monopropionate (17-BMP), the active metabolite of BDP, was evaluated in blood from the right atrium in four patients. Thirty-three of 42 (79%) placebotreated patients experienced a decrease of the DL CO from pretransplant to day 80 after transplant, compared with 27 of 49 (55%) BDP-treated patients (P ¼ 0.02). In the first 200 days after randomization, there were no cases of non-infectious pulmonary complications in BDP-treated patients, vs four cases among placebo-treated patients (P ¼ 0.04). Levels of 17-BMP were detected in atrial blood at steady state. Delivery of a potent glucocorticoid such as 17-BMP to the pulmonary artery after oral dosing of BDP may be useful in modulating pulmonary inflammation and preventing the development of noninfectious pulmonary complications after allogeneic HCT.
Introduction
Pulmonary complications after allogeneic hematopoietic cell transplantation (HCT) remain a major cause of morbidity and mortality. Among the estimated 50 000 to 60 000 hematopoietic cell transplants performed each year (www.ibmtr.org), approximately 30 to 60% of the transplant recipients will experience a pulmonary complication.
1,2 Although significant progress has been made in the prevention, diagnosis and treatment of opportunistic pulmonary infections, particularly infections caused by viral and fungal infections, no advances have been made in the prevention, diagnosis and treatment of HCT-related early non-infectious pulmonary syndromes such as idiopathic pneumonia syndrome (IPS) and diffuse alveolar hemorrhage. These syndromes represent diffuse interstitial non-infectious pulmonary processes that are suspected to be caused by a spectrum of insults, including the toxic effects of conditioning regimens, immunologic cellmediated injury, inflammatory cytokines or occult pulmonary infections [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] When these syndromes occur, they are associated with a high mortality rate of 60-100%, despite aggressive support in a critical care setting and treatment with high-dose systemic corticosteroids.
Two multicenter randomized placebo-controlled, doubleblind trials have been conducted to examine whether oral beclomethasone dipropionate (BDP) is an effective therapy for treatment of gastrointestinal GVHD. 15, 16 The results of these studies indicate that oral BDP is effective for treating gastrointestinal GVHD, allowing rapid taper and less use of systemic corticosteroid therapy, and resulting in a 45% reduction in mortality risk at 1 year post-randomization. In addition to these benefits, the most recent multicenter trial revealed that BDP treatment was also associated with fewer CMV reactivations (28 vs 39%), fungal infections, (7 vs 14%) and multiple bacteremic episodes (none vs 9%). 15 Of interest to the pulmonary community was an observation in the phase II study that 12 of 67 (18%) patients on the placebo arm had developed noninfectious pulmonary infiltrative disorders, compared with 0 of 62 patients in the BDP treatment arm. 17 On the basis of this initial observation, we developed the hypothesis that oral BDP may be effective in preserving lung function and preventing the development of early non-infectious pulmonary complications after allogeneic HCT. However, recognizing the potential for misclassification among different centers, we decided to test this hypothesis by evaluating all patients who participated in both randomized trials conducted at our Center. The current analysis was restricted to patients treated at our Center because all patients at our Center were evaluated using standardized prospective pulmonary evaluations and a clinical evaluation algorithm in place during both randomized trials. In addition, our Center has near complete follow-up of all clinical events after discharge from our Center through the Long Term Follow-up Clinic. 16 
Patients and methods

Patient selection
All Fred Hutchinson Cancer Research Center (FHCRC, also referred to as Center) patients enrolled in two randomized placebo-controlled trials of oral BDP for the treatment of acute gastrointestinal GVHD were included in the current analysis. 15, 16 The first study was a single center Phase 2 trial conducted between 1994 and 1996 that enrolled 60 patients; 29 received oral BDP 8 mg/day and 31 received placebo. 16 The second study was a multicenter Phase 3 trial conducted between 2001 and 2005 that enrolled a total of 129 patients, including 60 patients at the FHCRC, of whom 31 received oral BDP and 29 received placebo. 15 Patients enrolled at other institutions were not included in this analysis because of the lack of pulmonary function monitoring and potential differences in clinical definitions of pulmonary syndromes (see below). Both protocols and the current retrospective review were approved by our Institutional Review Organization.
Description of randomized placebo-controlled, double-blind trials of oral BDP Details of the two randomized trials have been previously described. 15, 16 Briefly, patients with biopsy-proven acute gastrointestinal GVHD received an induction course of prednisone (1 mg/kg/day for 10 days) plus either oral BDP pills (8 mg/day in four divided doses, half of each dose as a gastric-release formulation and half of each dose as an enteric-coated formulation) or placebo. Patients whose symptoms were controlled at study day 10 continued on the study drug, whereas the prednisone dose was rapidly tapered. Patients whose symptoms required additional prednisone were considered treatment failures; the study drug was discontinued on the day of treatment failure. The duration of treatment with the study drug was 30 days with a 10-day follow-up period in the first trial 16 and 50 days with a 30-day follow-up period in the second trial. On the basis of recommendations from the US Food and Drug Administration, all patients in the Phase III study were followed for clinical events until day 200 after randomization. 15 At our Center, detailed information about patient outcomes during the first year after transplant is gathered by our Long-Term Follow-Up office. Although the day 200 post-randomization end point had not been pre-specified in the protocol for the Phase II study of oral BDP vs placebo, all patients in the Phase II study were also followed through our Long Term Follow-Up office using identical clinical protocols.
Pulmonary function testing
All pulmonary function tests (PFT) were performed at our Center according to the American Thoracic Society guidelines. [18] [19] [20] Pulmonary function assessments included forced vital capacity (FVC), one-second forced expiratory volume (FEV 1 ), total lung capacity (TLC) and carbon monoxide diffusion capacity (DL CO ), which was adjusted for Hb level at the time PFTs were obtained. All PFT values were expressed as a percent of the predicted value calculated according to published equations. 21, 22 As part of our standard practice, pretransplantation and day-80 PFTs were obtained regardless of the presence or absence of symptoms. For the purposes of this study, we considered PFTs performed between days 60 and 100 as valid for the day-80 PFT. Before we began data collection, we defined an evaluable patient for the analyses involving day-80 PFTs as one who received a study drug for at least 5 days before the day-80 test to ensure that patients had adequate study drug exposure. Change in lung function was assessed by comparing PFT parameters performed before the start of conditioning with those obtained post transplantation at day 80. Analysis of change in lung function was performed by randomization assignment to oral BDP or placebo, with maintenance of the study blind.
Clinical follow-up and categorization of pulmonary disease after HCT All patients in both trials were monitored according to the Standard Practice Manual of the FHCRC, whereas at our Center, this included daily evaluation for pulmonary symptoms, the presence of which would prompt physiologic and radiographic evaluation, followed by pulmonary and infectious diseases subspecialty consultation when deemed appropriate. Microbiological studies are pursued according to recommendations from these services, which includes bronchoscopy with bronchoalveolar lavage when an abnormality suspicious for infection is noted on chest imaging. When indicated, lung biopsy was pursued. On discharge from our Center, the patients are followed by the Long Term Follow-Up office, which remains in close contact with the patient and their health-care provider for the first year after transplant. Should pulmonary issues arise, recommendations are made according to our Standard Practice Manual. All recommendations and clinical events are documented in our electronic records, which were reviewed for case designation.
While blinded to randomization assignment, two investigators (JWC and MS) reviewed all patients' pulmonary radiological records accumulated from the time of randomization. The medical records of all patients with abnormal pulmonary radiological findings were reviewed to determine whether the pulmonary disease was a clinically significant non-infectious or infectious syndrome. Clinically significant non-infectious pulmonary syndromes included IPS, defined as widespread alveolar injury in the absence of active lower respiratory tract infection after HCT; 23 diffuse alveolar hemorrhage, defined as IPS with bronchioalveolar lavage showing progressively bloodier return; 5 or biopsy-proven cryptogenic organizing pneumonia, otherwise known as bronchiolitis obliterans organizing pneumonia. 24, 25 All clinically significant pulmonary infections required microbiological documentation of an infectious agent in the respiratory tract through bronchoscopy or resolution of pulmonary abnormalities after empirical antibiotic therapy with no addition of immunosuppressive agents.
Measurement of 17-beclomethasone monopropionate in blood from the right atrium Four FHCRC patients enrolled in the Phase 3 randomized study had participated in an analysis of BDP pharmacokinetics. At study day 50, blood was drawn from the right atrium through an indwelling Hickman catheter at frequent intervals after a morning dose of oral BDP 2 mg (1 mg each in gastric-release and enteric-coated tablets). Blood samples were collected over EDTA, plasma was collected after centrifugation at 4 1C, and aliquots were frozen at À20 1C until analysis for BDP and 17-beclomethasone monopropionate (17-BMP) using high-pressure liquid chromatography and mass spectroscopy (MDS Pharma Services, Montreal, Canada). Pharmacokinetic parameters were calculated using WinNonlin v.2.1 (Pharsight Corp, Palo Alto, CA, USA). Plasma concentration-time data were plotted and non-compartmental parameters were calculated using the linear trapezoidal rule. Estimates for halflives were obtained using regression analysis by specifying an appropriate range of time points for the most linear portions of the log concentration-linear time data.
Statistical analysis
All statistical analyses were performed using SAS (version 8.2; SAS Institute, Cary, NC, USA), R (freeware; version 2.0.1) and S-Plus (version 6.2; Insightful, Seattle, WA, USA) software. Pp0.05 was considered statistically significant. Change in PFT parameters was analyzed by comparing the proportion of patients in the treatment groups who experienced a decrease of each PFT parameter from pretransplantation to day 80 using the w 2 -test. 26 Average change from baseline to day 80 was compared using the two-sample t-test. Cumulative incidence curves were used to summarize the probability of the time-to-event end points of non-infectious and infectious pulmonary events, where death without the respective pulmonary event was considered a competing risk. 27 For these end points, the hazard ratio for failure was estimated on the basis of a Cox proportional hazards model that included a term for the treatment group. 28 No additional covariates were included in the model for non-infectious complications because of the low number of events in the study. Patients alive without failure for the pulmonary time-to-event end points at day 200 after randomization were censored at these times as appropriate.
Results
There were 120 randomized patients from our Center available for this analysis, of whom 60 received oral BDP and 60 received placebo. The characteristics of these patients are summarized in Table 1 . In the analysis of change in PFTs from baseline to day 80, eight patients who did not meet the minimum 5-day criterion of treatment with the study drug before their day-80 PFT were not included (five in the placebo group, three in the BDP group). The median time to randomization was 33.5 days after HCT (range, 19-105) for the Phase 2 study and 31 days (range, 16-89) for the Phase 3 study. The mean number of days from the randomization date to the first of the day-80 PFT date/study drug stop date is 26.4 days for the placebo group and 27.7 days for the BDP group (P ¼ 0.69). No patient received chest irradiation directly, but one patient received spinal irradiation for cord compression caused by lymphoma (25 Gy to T6-T8 and 20 Gy to C6-T2); this patient was randomized to receive placebo. Two patients received total 12 Gy body irradiation as part of their conditioning regimen for earlier hematopoietic cell transplants; both were randomized to receive oral BDP.
Several patients were missing baseline and day-80 PFTs, as indicated by the total number of patients contributing to the appropriate analyses summarized below and in Table 2 . Overall, the majority of patients had normal pulmonary function before transplantation, defined as a percentage of the normal predicted value X80% (FVC 94/114 (82%); Changes in pulmonary function from pretransplantation to day 80 after transplantation are summarized in Table 2 . The proportion of BDP-and placebo-treated patients who experienced a decrease (of any magnitude) of their pulmonary function from pretransplantation to day 80 after transplantation was similar for FVC, FEV 1 and TLC, with no statistically significant differences. There was, however, a statistically significant difference in the proportion of patients who experienced a decrease of the DL CO (33 of 42 (79%) among placebo-treated patients, 27 of 49 (55%) in the BDP group, P ¼ 0.02). Among placebotreated patients, the mean DL CO change was À7.95% (median, À7.17%; range À40 to þ 24%), whereas the mean change from baseline to day 80 was þ 0.57% for BDPtreated patients (median, À0.61%; range À74 to þ 115%), and the P-value did not exceed the 0.05 threshold (P ¼ 0.08). These results were not qualitatively changed after adjusting for intensity of conditioning (reduced intensity vs myeloablative) (P ¼ 0.009 for proportion experiencing a decrease in DL CO decrease; P ¼ 0.05 for the mean DL CO decrease) or after adjusting for age (P ¼ 0.07 for proportion experiencing a decrease in DL CO ; P ¼ 0.02 for the mean DL CO decrease).
Among 60 placebo-treated patients, four non-infectious complications occurred within the first 200 days after randomization (Figure 1 ). These cases were cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia (at day 39) and IPS (at days 69, 148 and 168). All of these cases occurred after a myeloablative conditioning regimen. Among 60 BDP-treated patients, there were no cases of non-infectious pulmonary complications during the first 200 days after randomization (Figure 1) . When considered as a time-to-event end point, the risk of developing a non-infectious complication within the first 200 days after randomization was reduced among BDPtreated patients, (asymptotic log-rank test, P ¼ 0.04; exact log-rank test, P ¼ 0.06). With only four events, it was not possible to adjust for any factors such as intensity of conditioning or age.
The causes of pulmonary infections are summarized in Table 3 . Among 60 placebo-treated patients, five cases of pulmonary infection occurred within the first 200 days after randomization (Figure 2 ). Among 60 BDP-treated patients, six cases of pulmonary infection occurred during the first 200 days after randomization (Figure 2) . Two of the noninfectious pulmonary complications cited occurred in the 1994-1996 time window, whereas the other two occurred in the later time window. When considered as a time-to-event end point, the risk of developing a pulmonary infection within 200 days after randomization was not statistically significantly different between the BDP and placebo groups (hazard ratio ¼ 1.21 (0.37-3.96, P ¼ 0.75)).
In four patients, peak concentrations of 17-BMP in right atrial blood were achieved at a median of 1.5 h after oral dosing of BDP 2 mg on the morning of study day 50. The median C max was 1738 pg/ml (range 632-3701). Median steady state exposure to 17-BMP was 5347 pg/h/ml (range 3273-5201) as estimated by AUC 0À4 h . The median half-life of 17-BMP was 6.3 h (range 3.1-6.8). No BDP was detected in right atrial blood.
Discussion
The current results suggest that in the context of the original randomized placebo-controlled trials of oral BDP, patients randomized to receive oral BDP were more likely to experience a preservation of pulmonary diffusing capacity and fewer episodes of non-infectious pulmonary complications compared with placebo-treated patients. These results are consistent with what is known about the pathophysiology of lung function loss and idiopathic lung injury in the aftermath of allogeneic HCT and the pharmacology of oral BDP and its potent metabolite, 17-BMP.
Our finding that DL CO decrease appears to be less pronounced among the BDP-treated patients is interesting. DL CO measures the patient's ability to absorb alveolar gases into the capillary blood flow, reflecting alveolar membrane thickness, hematocrit level, cardiac output and heterogeneity in the distribution of the diffusion capacity to regional ventilation and perfusion (in patients with pulmonary disease). 29, 30 It is well known that systemic inflammation, such as that which can occur in the early post transplant period, can result in pulmonary inflammation, which ultimately can cause a thickening of the pulmonary interstitium and decreased DL CO . In such a setting, the direct delivery of BDP to the pulmonary interstitium through the pulmonary artery may serve to reduce inflammation within the lungs, thereby minimizing the DL CO reduction commonly observed after allogeneic HCT.
According to a National Institutes of Health workshop, IPS is loosely defined as 'evidence of widespread alveolar injury in the absence of active lower respiratory tract infection.' 3 In the modern era of HCT, early HCT-related non-infectious pulmonary complications such as IPS generally occur within the first 6 months after transplantation, 24 with a reported incidence of 3-15%. [31] [32] [33] There is an accumulating body of evidence from murine models of lung injury after allogeneic HCT that strongly suggests that inflammation has a significant role in the pathogenesis of IPS. Some of these murine studies have established a causal role for TNF-a in the development of IPS, where the administration of a TNF-a-binding protein (rhTNFR:Fc) reduces the progression of lung injury during the 4-to 6-week period after HCT. 12, 34, 35 Other studies have also suggested that lipopolysaccharide, which often gains access to systemic circulation early in the post transplantation period by translocating across gut mucosa damaged by conditioning regimens and acute GVHD, [36] [37] [38] may result in a significant inflammatory cytokine milieu in the lung that results in lung injury. 7, 37 Collectively, these data provide strong evidence that overwhelming inflammation within the lungs likely has a significant role in the pathogenesis of early non-infectious pulmonary complications after HCT. The direct delivery of a potent corticosteroid such as oral BDP to the lungs through the pulmonary circulation may Table 2 Change in pulmonary function from pretransplant to day 80
PFT parameter Placebo BDP P-value Days after randomization Probability of non-infectious complication Figure 1 Cumulative incidence of non-infectious pulmonary complications after treatment randomization. Before day 200 after treatment randomization, no cases of non-infectious pulmonary complications occurred among the beclomethasone dipropionate-treated patients. attenuate the inflammation and prevent the development of IPS. An alternative biological explanation for the positive effects of oral BDP on these pulmonary end points is that less gut GVHD reduces gut translocation of bacteria and endotoxin and thus reduces pulmonary exposure to translocated lipopolysaccharide and inflammatory cytokines. However, we feel that this mechanism is less likely than that of pulmonary delivery of the potent metabolite 17-BMP because the primary site of 17-BMP activity in patients enrolled in these protocols was the upper gut, not the colon, which is where Gram-negative bacteria primarily reside and lipopolysaccharide translocation occurs. Oral formulations of BDP were developed for treatment of inflammatory bowel disease, where they proved to be effective. [39] [40] [41] However, although inhaled BDP has been used for the treatment of asthma and chronic inflammatory airway disease for over 35 years, 42 oral BDP does not seem to have been evaluated for the treatment of pulmonary diseases, perhaps because of the assumed adverse effects associated with systemic corticosteroid therapy. The formulations of oral BDP used in the randomized trials described here included a gastric-release pill for distribution of BDP to the stomach and upper small intestine, and an enteric-coated pill for distribution to the distal small intestine and colon. The presence of 17-BMP in the blood from the right heart, as shown by our data, suggests that 17-BMP, a product of gastrointestinal mucosal hydrolysis of BDP, was likely absorbed in the gastrointestinal tract and entered the right heart through the portal venous circulation. In the HCT situation, we speculate that steadystate delivery of 17-BMP to the pulmonary circulation and ultimately the interstitial space before the onset of clinically detectable disease was responsible for reducing pulmonary inflammation, reflected by the preservation of pulmonary diffusing capacity and by the absence of non-infectious pulmonary infiltrates within the first 200 days after randomization.
Oral BDP also has several advantages over other corticosteroid options from a pharmacodynamics perspective. First, although BDP itself is a relatively weak immunosuppressive glucocorticoid, its active metabolite 17-BMP is a highly potent glucocorticoid; 17-BMP is 3.6-times more potent than triamcinolone-16,17-acetonide, the active ingredient in Azmacort inhalation aerosol (Abbott, Parsippany, NJ, USA) and 450 times more potent than dexamethasone. 43 Second, as 17-BMP's glucocorticoid receptor-a activity is 13 times more potent than dexamethasone, 44 it can be administered at significantly lower doses. Third, owing to the pulmonary 'first pass' effect, higher 17-BMP concentration can be achieved in the lung with relatively small doses. Small doses of 17-BMP can be delivered to the pulmonary artery in milligram quantities per day after ingestion of 8 mg oral BDP, which is four-to eightfold higher than can be delivered through inhaled BDP. Finally, the relative bioavailability of BDP and its metabolites is much lower in comparison with more commonly used systemic corticosteroids. In a bioavailability study of oral BDP, no BDP was detectable in the plasma after oral administration. Although the total oral bioavailability of the active metabolite 17-BMP was 21-41%, 45 systemic exposure to 17-BMP is limited by its protein binding and clearance, such that oral BDP 2 mg would give systemic exposure equivalent to a dosing schedule of oral prednisone of 2.5 mg or less than 1 mg of i.v. dexamethasone (DOR BioPharma Inc., Princeton, NJ, USA, unpublished data). These factors, in conjunction with the fact that distribution of 17-BMP into the pulmonary interstitial space is likely considerably greater with pulmonary artery delivery than the inhaled route, make oral BDP worthy of further investigation for pulmonary diseases rooted in any inflammatory pathophysiology.
Several limitations should be recognized when interpreting the results of this study. First, as the original trials were neither powered nor designed to address pulmonary issues, they are not optimal for examining the true potential of oral BDP as a prophylaxis therapy for non-infectious pulmonary complications. Such a study would require the intervention to be initiated at the time of transplant and probably with a longer duration of treatment, not to mention a substantially larger number of patients. Second, the size of the current study is limiting not only with respect to statistical power but also because we were not able to adjust for important factors that may influence the risk for developing non-infectious complications. For instance, despite the randomized design, more patients in the oral BDP arm of the phase III study received a reducedintensity conditioning regimen, which has been previously found to be associated with a lower incidence of IPS. 24 However, despite the small number of non-infectious pulmonary events, we do believe that our observations are unlikely to be attributable to statistical chance. In a recent conservative analysis of the prevalence of IPS among reduced intensity regimen recipients, it is estimated that IPS should occur in 2.2% of the population, which means there should have been at least one case observed among the placebo-treated patients. 24 Third, although the DL CO results are interesting, the DL CO data need to be interpreted with caution. The clinical implication of small percentage changes in DL CO , such as those we have detected, are not readily obvious, especially in a transplant setting, where there are many clinical variables that can influence DL CO . Oral BDP (n=60) Figure 2 Cumulative incidence of pulmonary infections after treatment randomization. There was no statistically significant difference in the risk of pulmonary infections between the two treatment groups.
In summary, the current data suggest that oral BDP treatment was associated with a lower incidence of noninfectious pulmonary complications and that delivery of a potent glucocorticoid (17-BMP) to the pulmonary artery may be useful in modulating pulmonary inflammation after allogeneic HCT. We emphasize that we consider these data to be hypothesis generating because of the limitations cited above. As such, these findings are not sufficient to justify the use of oral BDP to prevent non-infectious pulmonary complications, but should guide future studies designed to definitively address the potential of BDP to lower the risk of non-infectious pulmonary complications and assess the potential adverse events associated with prolonged oral BDP use.
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